Survodutide (BI 456906) is a dual agonist targeting glucagon and GLP-1 receptors, aimed at treating obesity. By activating both receptors it enhances energy expenditure through glucagon receptor-mediated pathways like gluconeogenesis, and simultaneously reduces appetite via GLP-1 receptor effects. A phase 1b study demonstrated significant weight reductions of up to 14.1% in 16 weeks with survodutide, outperforming placebo. The preclinical trials have shown outcomes than those, with semaglutide for long term obesity management and metabolic enhancements suggestive as a significant advancement, in the field.
Le Roux, P.C.W., Steen, O., Lucas, K.J., Startseva, E., Unseld, A. and Hennige, A.M. (2024). Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. The Lancet Diabetes & Endocrinology.
Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.
For more details consult with your doctor or healthcare professional.
Le Roux, P.C.W., Steen, O., Lucas, K.J., Startseva, E., Unseld, A. and Hennige, A.M. (2024). Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. The Lancet Diabetes & Endocrinology.
Le Roux, P.C.W., Steen, O., Lucas, K.J., Startseva, E., Unseld, A. and Hennige, A.M. (2024). Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. The Lancet Diabetes & Endocrinology.
Le Roux, P.C.W., Steen, O., Lucas, K.J., Startseva, E., Unseld, A. and Hennige, A.M. (2024). Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. The Lancet Diabetes & Endocrinology.
Home
